Abstract
Hypoxia initiates an adaptive physiological response in all organisms and plays a role in the pathogenesis of several human diseases. The hypoxia/HIF-inducible factor-1 (HIF-1) transcription factor mediates transcriptional responses to hypoxia by binding to a cis-acting hypoxia-responsive element (HRE) present within target genes. The use of the HIF-1/HRE system of gene regulation can be utilized as a mechanism to target expression of therapeutic genes to hypoxic cells or cells that have a constitutively active HIF-1/HRE pathway due to cell transformation. Given the rapid resistance of tumors to single therapeutic strategies, new vector systems need to be developed that can deliver multimodal therapy. Here we show that HREs function as classical enhancer elements and function bidirectionally to co-regulate the expression of two genes. We designed a large series of novel bidirectional hypoxia/HIF-responsive expression vectors using HREs derived from the human vascular endothelial growth factor (VEGF) and erythropoietin (EPO) genes. We measured the ability of these constructs to express the luciferase and LacZ/β-galactosidase (β-gal) reporter genes bidirectionally under normoxic (21% O2) versus hypoxic (1, 3, 5, and 10% O2) conditions by transient transfection in three human glioma cell lines (LN229, U251MG and U138MG). Nine constructs were identified that exhibited moderate to high inducibility at 1% O2 while maintaining tight regulation under normoxic conditions. Moreover, the level of activation was a function of O2 concentration and was exponential at O2 levels below 5%. These vectors will be valuable tools in a variety of gene therapy applications targeting pathological activation of the HIF-1/HRE pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Semenza GL . HIF-1 and human disease: one highly involved factor Genes Dev 2000 14: 1983–1991
Brown JM, Giaccia AJ . The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res 1998 58: 1408–1416
Brown JM . Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies Mol Med Today 2000 6: 157–162
Semenza GL . Hypoxia, clonal selection, and the role of HIF-1 in tumor progression Crit Rev Biochem Mol Biol 2000 35: 71–103
Wenger RH, Gassmann M . Oxygen(es) and the hypoxia-inducible factor-1 Biol Chem 1997 378: 609–616
Dvorak HF et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation Int Arch Allergy Immunol 1995 107: 233–235
Dachs GU et al. Targeting gene expression to hypoxic tumor cells Nat Med 1997 3: 515–520
Prentice H et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium Cardiovasc Res 1997 35: 567–574
Boast K et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease Hum Gene Ther 1999 10: 2197–2208
Shibata T, Giaccia AJ, Brown JM . Development of a hypoxia-responsive vector for tumor-specific gene therapy Gene Therapy 2000 7: 493–498
Modlich U, Pugh CW, Bicknell R . Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers Gene Therapy 2000 7: 896–902
Koshikawa N et al. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells Cancer Res 2000 60: 2936–2941
Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer Gene Therapy 1999 6: 1721–1727
Griffiths L et al. The macrophage – a novel system to deliver gene therapy to pathological hypoxia Gene Therapy 2000 7: 255–262
Ruan H et al. Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX Neoplasia 1999 1: 431–437
Semenza GL, Wang GL . A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation Mol Cell Biol 1992 12: 5447–5454
Liu Y et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer Circ Res 1995 77: 638–643
Shibata T et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes Int J Radiat Oncol Biol Phys 1998 42: 913–916
Baron U et al. Co-regulation of two gene activities by tetracycline via a bidirectional promoter Nucleic Acids Res 1995 23: 3605–3606
Acknowledgements
This work was supported by grants NS41403, CA86335 and CA87830 from the NIH, the Charlotte Geyer Foundation, the Pediatric Brain Tumor Foundation of the US, The Brain Tumor Society, and MBNA, NA. Oligonucleotides were synthesized by the Emory University Microchemical Core Facility.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Post, D., Van Meir, E. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 8, 1801–1807 (2001). https://doi.org/10.1038/sj.gt.3301605
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301605
Keywords
This article is cited by
-
A Chinese herbal decoction, Jian-Pi-Yi-Shen, regulates the expressions of erythropoietin and pro-inflammatory cytokines in cultured cells
BMC Complementary and Alternative Medicine (2018)
-
RSUME inhibits VHL and regulates its tumor suppressor function
Oncogene (2015)
-
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma
Cancer Chemotherapy and Pharmacology (2015)
-
Detailed assessment of gene activation levels by multiple hypoxia-responsive elements under various hypoxic conditions
Annals of Nuclear Medicine (2014)
-
A novel hybrid promoter responsive to pathophysiological and pharmacological regulation
Journal of Molecular Medicine (2012)